# To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

> **NCT02260804** · PHASE3 · COMPLETED · sponsor: **Celltrion** · enrollment: 258 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** CT-P10
- **BIOLOGICAL:** Rituxan

## Key facts

- **NCT ID:** NCT02260804
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2018-01-04
- **Final completion:** 2019-09-04
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260804, "To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02260804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*